Eagle Asset Management Inc. boosted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 1.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,768,660 shares of the biopharmaceutical company’s stock after purchasing an additional 51,260 shares during the quarter. Eagle Asset Management Inc. owned about 1.09% of Amicus Therapeutics worth $22,204,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Point72 Hong Kong Ltd purchased a new stake in Amicus Therapeutics in the 2nd quarter worth approximately $49,000. US Bancorp DE raised its position in shares of Amicus Therapeutics by 50.9% during the 2nd quarter. US Bancorp DE now owns 4,896 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 1,651 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Amicus Therapeutics during the 2nd quarter valued at $73,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. purchased a new stake in shares of Amicus Therapeutics during the 2nd quarter valued at $122,000. Finally, Weil Company Inc. purchased a new stake in shares of Amicus Therapeutics during the 2nd quarter valued at $125,000.
NASDAQ:FOLD traded up $0.02 during trading hours on Friday, reaching $8.94. The company’s stock had a trading volume of 3,123,500 shares, compared to its average volume of 3,303,875. Amicus Therapeutics, Inc. has a 1 year low of $7.11 and a 1 year high of $14.61. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of -6.72 and a beta of 1.58. The firm has a 50-day simple moving average of $8.39 and a 200-day simple moving average of $10.88. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.97 and a current ratio of 7.09.
Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.34). The company had revenue of $44.13 million during the quarter, compared to analysts’ expectations of $41.14 million. Amicus Therapeutics had a negative net margin of 336.41% and a negative return on equity of 66.79%. Amicus Therapeutics’s revenue was up 107.1% on a year-over-year basis. During the same period last year, the company posted ($0.33) EPS. Equities analysts anticipate that Amicus Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.
Several research firms have recently weighed in on FOLD. ValuEngine cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Cantor Fitzgerald restated an “overweight” rating on shares of Amicus Therapeutics in a research report on Thursday, October 17th. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Amicus Therapeutics in a research report on Monday, October 14th. BidaskClub upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, November 5th. Finally, Zacks Investment Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 price objective on the stock in a research report on Monday, November 4th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Amicus Therapeutics presently has an average rating of “Buy” and a consensus price target of $17.72.
In related news, Director Burke W. Whitman acquired 4,945 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was purchased at an average cost of $10.07 per share, with a total value of $49,796.15. Following the completion of the acquisition, the director now directly owns 21,612 shares of the company’s stock, valued at $217,632.84. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John F. Crowley sold 14,500 shares of the business’s stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $8.01, for a total transaction of $116,145.00. Following the transaction, the chief executive officer now directly owns 735,694 shares of the company’s stock, valued at $5,892,908.94. The disclosure for this sale can be found here. 2.50% of the stock is currently owned by insiders.
Amicus Therapeutics Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Read More: Preferred Stock
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.